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Plasma phospholipid lipid transfer protein (PLTP) has several known key functions in lipoprotein metabolism. Recent studies suggest that it
also may play a role in the inflammatory response. Inflammatory cell activity contributes to the development of atherosclerosis. To seek further
evidence for the association of PLTP with inflammation, we studied the relationship between PLTP activity and five inflammatory markers
[C-reactive protein (CRP), serum amyloid A (SAA), interleukin 6 (IL-6), white blood cells (WBC), and fibrinogen] in 93 patients with low HDL and
cardiovascular disease (CVD). Plasma PLTP activity had the strongest correlation with CRP (r =0.332, P <0.001) followed by SAA (r =0.239,
P=0.021). PLTP, CRP, and SAAwere significantly associated with body mass index (BMI), insulin or glucose, apolipoprotein (apo) B, and/or apo E
level (r =0.264–0.393, P <0.01). PLTP, SAA, and IL-6 also were associated with the concentration of HDL particles without apo A-II
[Lp(A-I)](r =0.373–0.472, P <0.005, n =56), but not particles with apo A-II. Smoking was associated with increased PLTP activity, CRP, and
WBC, and hypertension with increased PLTP activity. In linear models, CRP remained significantly associated with PLTP after adjustment of CVD
risk factors and insulin resistance. Also, much of the variability of plasma PLTP activity was explained by CRP, BMI, Lp(A-I), smoking, glucose,
and blood pressure. These findings show for the first time that plasma PLTP activity is associated positively with CRP in CVD, a state of chronic
inflammation.
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Human plasma phospholipid transfer protein (PLTP) is a
glycoprotein with a calculated protein molecular weight of 54.7
kDa but an apparent molecular weight of approximately 80
kDa on SDS gel electrophoresis due to glycosylation ([1]
review). PLTP belongs to a gene family of lipid transfer
proteins that includes bactericidal/permeability-increasing pro-
tein (BPI), lipopolysaccharide binding protein (LBP), and
cholesteryl ester transfer protein (CETP) [1]. It was initially
described as a lipid transfer protein that facilitates the transfer
of phospholipid from very-low density lipoproteins (VLDL) to
high-density lipoproteins (HDL) [2]. Subsequent studies0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.09.002
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E-mail address: mccheung@u.washington.edu (M.C. Cheung).demonstrated that it could also bind and transfer unesterified
cholesterol [3] and a-tocopherol [4] among lipoproteins and
between lipoproteins and cells. In addition, it can transfer
lipopolysaccharide from gram-negative bacteria to lipoproteins
[5] and interact with the ATP-binding cassette transporter A1
(ABCA1) [6]. With the ability to interact with ABCA1, to bind
and transfer lipids and other biologically active molecules,
PLTP appears to be a multifaceted protein with diverse
biological functions. To date, PLTP has been shown to be an
important modulator of the level and composition of circulating
lipoproteins in vitro ([7] review) and in mouse models ([8]
review). It can also enhance lipid efflux from cultured cells
[6,9], modify the anti-oxidative potentials of lipoproteins and
tissues [4,7], and may attenuate the host response to
lipopolysaccharide [5,7]. Recently, it was reported that PLTP
was increased in patients with systemic and acute inflammatory1762 (2006) 131 – 137
http://www
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with inflammatory activity.
There is now abundant evidence that inflammatory cell
activity contributes to atherogenesis [12], and multiple
inflammatory markers such as C-reactive protein (CRP), serum
amyloid A protein (SAA), fibrinogen, white blood cell (WBC),
and interleukin 6 (IL-6) are associated with increased risk of
atherosclerosis [13–15]. In addition, PLTP has been implicated
in human atherosclerosis, where it has been detected both on
macrophage foam cells and on extracellular matrix [16]. To
seek further evidence of a role for PLTP in inflammation, we
sought to determine if there existed a positive association
between PLTP and known inflammatory markers in a group of
patients with cardiovascular disease (CVD) documented by
angiography.
2. Materials and methods
2.1. Study patients and blood samples
The patients included in these analyses are participants of the HDL-
Atherosclerosis Treatment Study (HATS), a clinical trial aimed at assessing the
effects of different lipid-altering strategies on coronary disease progression/
regression. One hundred and thirty-four patients were enrolled in Seattle,
Washington and 26 patients in Vancouver, British Columbia. Details on the
design and the major outcome of the study have been reported [17,18]. All
patients had clinical coronary disease (prior myocardial infarction, angioplasty,
or positive exercise tolerance test), and all demonstrated coronary stenosis in one
or more vessels by angiography. All had low HDL cholesterol (<0.90 mmol/l or
35 mg/dl) for men and <1.03 mmol/l or 40 mg/dl for women), and normal
LDL-C (<3.75 mmol/l or 145 mg/dl) on at least one visit prior to randomization.
The study was approved by the Human Subjects Review Committee of the
University of Washington and the Institutional Review Board of the St Paul’s
Hospital, University of British Columbia and informed consent was obtained
from all subjects before entering the study. Venous blood was drawn at pre-
treatment baseline after a 12- to 14-h overnight fast and was processed according
to the protocols of the laboratories performing the tests. Plasma was promptly
separated by low-speed centrifugation at 4 -C and immediately used for lipid,
lipoprotein, apolipoprotein (apo), glucose, fibrinogen, and other analyses, and
for HDL particle isolation. Aliquots of the plasma samples were also
immediately frozen at 70 -C for PLTP activity, CRP, SAA, IL-6, and insulin
measurements. Only baseline samples obtained at the randomization visit were
used in the present study.
2.2. PLTP activity
The plasma phospholipid transfer activity mediated by PLTP was
determined in 93 of the 160 HATS patients by measuring the transfer of
14C-phosphatidylcholine from phospholipid liposomes to HDL using an
established radioassay [19]. Aliquots from three frozen plasma samples with
low, medium, and high PLTP activities were included in each assay to control for
inter-assay variation. The mean intra- and inter-assay coefficients of variation
for these control samples were 4.0% and 6.4%, respectively.
2.3. CRP, SAA, and IL-6
Plasma CRP and SAA levels were determined by highly sensitive
nephelometric assays (Behring Diagnostics). For the CRP assay, the lower
limit of detection was 0.2 mg/l and the coefficient of variation was 5–9%. For
the SAA assay, the lower limit of detection was 0.8 mg/l and the coefficient of
variation was 4–8%. Interleukin-6 was measured using a Biosource ELISA Kit
with the lower limit of detection of 2 pg/ml (Biosource International). CRP,
SAA, and IL-6 were analyzed at the Clinical Nutrition Research Unit of the
University of Washington.2.4. Other laboratory analyses
VLDL, intermediate-density lipoproteins (IDL), low-density lipoproteins
(LDL) and HDL were separated by conventional ultracentrifugation and
precipitation methods. HDL particles without apo A-II [Lp(A-I)] and with apo
A-II [Lp(A-I, A-II)] were isolated by sequential dextran sulfate, anti-A-II, and
anti-A-I affinity column chromatography [20]. Lipids in plasma and fraction-
ated lipoproteins were analyzed by enzymatic methods, and apolipoproteins
A1, A-II, B, and E were measured with nephelometric assays (Behring
Diagnostic). Insulin was measured with a double-antibody radioimmunoassay.
All lipid and apolipoprotein analyses were performed at the Northwest Lipid
Research Laboratories; insulin was measured at the Diabetes Endocrinology
Research Center; and fibrinogen, WBC, and fasting blood glucose were
measured at the clinical laboratories of the University of Washington.
Homeostatic model assessment (HOMA) of ß-cell function and insulin
resistance was calculated from fasting glucose and insulin as described [21].
2.5. Statistical analyses
Data were summarized by mean, median, and standard deviation, number,
and percent, or median and 25th–75th percentile where appropriate. To
minimize any possible contribution of outliers, the Mann–Whitney U test was
used for group comparisons, and Spearman rank order correlation analyses
were used to determine the relationships between PLTP and the inflammatory
factors as well as between PLTP or the inflammatory factors and metabolic and
lipoprotein parameters. Multiple linear regression analysis was used to examine
predictors of PLTP activity controlling for CVD risk factors. As the
distributions of CRP and SAA were skewed, their logarithmically transformed
values were used in multiple regression analyses. In consideration of multiple
comparisons, only results with P <0.01 (two tailed) are reported as significant
unless otherwise indicated. All calculations were carried out using SPSS
statistical software.
3. Results
3.1. Subject characteristics
The 93 HATS patients in this report are the combined
subjects in two earlier studies carried out to determine the
relationship between plasma PLTP activity and HDL subfrac-
tions [22] and the effect of simvastatin and niacin treatment on
plasma PLTP activity [23]. They include all 61 patients in the
Seattle cohort randomized to take simvastatin plus niacin or
their placebos, and the first 32 patients in the Seattle cohort
randomized to take either antioxidant supplements alone or in
combination with simvastatin and niacin. There were 87 men
and 6 women ranging in age between 37 and 71 years. Sixty-
eight percent of the patients were obese (BMI>27.5 kg/m2);
13% of the patients had been diagnosed with Type 2 diabetes;
45% had a history of hypertension; 46% and 25% were past
and present smokers, respectively; and 55% had a history of
myocardial infarction. The mean severity of proximal stenosis
at baseline was 34.7%. These characteristics (Table 1) and the
lipid and lipoprotein profile (Table 2) of these subjects are
comparable to those reported for the entire HATS patient
population [17].
3.2. PLTP activity and inflammatory markers
Plasma levels of PLTP activity and of the five inflammatory
markers for CVD evaluated in this study are shown in Table 2.
The levels of CRP, SAA, fibrinogen, IL-6, and WBC in these
Table 2
Lipoprotein and inflammatory marker levels
MeanTS.D. (Median) Range
Plasma cholesterol (mg/dL) 199T32 (199) 129–297
Plasma triglyceride (mg/dL) 213T96 (186) 40–503
IdL cholesterol (mg/dL) 15T6 (15) 2–34
LdL cholesterol (mg/dL) 127T30 (125) 64–207
HdL cholesterol (mg/dL) 31T4 (31) 20–41
HdL Triglyceride (mg/dL) 14T6 (14) (2–36)
Apo AI (mg/dL) 108T14 (108) 65–151
Apo B (mg/dL) 118T23 (117) 66–174
Apo E (mg/dL) 4.8T1.4 (4.5) 2.3–11.5
Apo A-I in Lp(A-I) (mg/dL) 21.8T7.2 (20.8) 9.1–43.9
PLTP activity (Amol/ml/h) 14.8T2.0 (15.0) 9.9–19.4
Inflammatory Markers Median
(25th–75th percentile)
Range
C-reactive protein (mg/L) 2.5 (1.0–5.5) 0.1–28.7
Serum amyloid A (mg/L) 2.8 (1.8–5.25) 0.7–208
Fibrinogen (g/L) 3.52 (3.13–4.19) 1.97–6.43
Interleukin-6 (pg/mL) 2.0 (1.9–4.0) 1.9–32.0
White blood cell (count/Al) (103) 6.6 (5.65–8.1) 2.9–13.2
Numbers are from 92 or 93 subjects except with Lp(A-I) (n =56) and
fibrinogen (n =89).
Table 1
Subject characteristics
MeanTS.D. (Median)
or N (%)
Range
Age (year) 52.9T7.7 (53.1) 37–71
Male 87 (94%) N/A
Body mass index (kg/m2) 29.6T3.9 (29.5) 19.3–39.0
Diabetes (Type 2) 12 (13%) N/A
Insulin (AU/ml) 23.9T13.9 (21.5) 6–90
Glucose (mg/dl) 103.3T32.5 (93.5) 70.5–259.5
History of hypertension 42 (45%) N/A
Systolic blood pressure
(mm Hg)
125.3T14.9 (124.0) 96–172
Diastolic blood pressure
(mm Hg)
79.5T8.4 (78.0) 58–102
Smokers (past/current) 43 (46%)/23 (25%) N/A
Cigarettes (no./day) 4.3T9.3 (0) (0–40)
Cigarettes (pack–years)a 22.1T22.0 (19.5) (0–80)
Previous myocardial infarction 51 (55%) N/A
Mean proximal stenosis (%) 34.7T10.5 (33.7) (14.7–62.0)
Numbers are from 92 or 93 subjects except with blood pressure (n =81) and
stenosis (n =88) measurements.
a (number of packs/day) (years of smoking).
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the entire HATS patient population [HATS population medians
(inter-quartile ranges) were CRP: 2.1 (0.83–5.2) mg/l; SAA:
2.8 (1.8–5.53) mg/l; fibrinogen: 3.49 (3.04–4.16) g/l; IL-6: 1.9
(1.9–4.0) pg/ml; WBC counts: 6.5 (5.6–8.1) 103/Al]. Of
these five inflammatory markers, PLTP activity was positively
and significantly associated with CRP (rs=0.332, P <0.001)
but not with fibrinogen, IL-6, or WBC counts (Table 3). A
similar significant correlation was observed between CRP and
PLTP activity after exclusion of the 12 diabetics (rs=0.339,
P=0.002, n=81) or exclusion of the diabetics and the 7
women (rs=0.347, P=0.002, n =76). An association approach-
ing significance was also seen between PLTP and SAA before
(rs=0.239, P=0.021, n =93) or after (rs=0.253, P=0.023,
n =81) exclusion of diabetics. Among the inflammatory
markers, CRP was strongly associated with SAA (rs=0.661,
P <0.001) and fibrinogen (rs=0.572, P <0.001), the other two
acute-phase proteins. Significant associations were also ob-
served between CRP and IL-6 (rs=0.321, P=0.002); CRP and
WBC (rs=0.264, P=0.010); SAA and fibrinogen (rs=0.349,
P <0.001); SAA and IL-6 (rs=0.283, P=0.006); and fibrino-
gen and WBC (rs=0.308, P=0.003).
3.3. PLTP, inflammatory markers, and CVD risk factors
The relationships of metabolic and lipoprotein CVD risk
factors with PLTP and the inflammatory markers were
analyzed. Those that demonstrated significant correlations are
shown in Table 4. Plasma PLTP activity, CRP, and SAA were
correlated positively and significantly with BMI, and apo E,
and with either insulin, glucose, or insulin resistance as
calculated by the homeostatic model assessment (HOMA)
method. Both PLTP and SAAwere also significantly correlated
with diastolic blood pressure and apo B. In addition, PLTP,
SAA and IL-6 were significantly associated with Lp(A-I)
(rs=0.373–0.472, P <0.005, n =56)) but not with Lp(A-I, A-II) (data not shown). The correlation between CRP and Lp(A-I)
also approached significance (rs=0.325, P=0.015, n =56). No
significant correlations were observed between fibrinogen and
the lipid or metabolic risk factors tested (data not shown). To
determine if the association between PLTP and CRP was
related to their mutual association with several metabolic and
lipid factors, linear regression analyses were performed. CRP
remained significantly associated with PLTP after controlling
for each of the risk factors except for Lp(A-I) (Table 5).
The effects of pro-inflammatory risk factors of CVD
(cigarette smoking, hypertension, and diabetes) on plasma
PLTP activity and on the inflammatory markers were also
studied. Cigarette smoking appeared to be associated with an
increase in WBC, fibrinogen, CRP and PLTP. Current smokers
(n=22) had significantly higher fibrinogen and WBC levels
compared to patients who were not smoking at the time they
entered the study (n =70) (median fibrinogen: 406 vs. 339 g/l,
P=0.009; WBC: 8.4 vs. 6.1103 counts/Al, P <0.001).
Cumulative cigarette smoking, expressed as pack-years [(num-
ber of packs/day) (years of smoking)], was associated with
raised levels of not only PLTP activity, but also of CRP and
WBC. Patients with cumulative cigarette smoking greater than
the median (i.e.19.5 pack-years) had higher levels of PLTP
activity, CRP, and WBC than did those who smoked less than
the median quantities (median PLTP activity: 15.21 vs. 14.64
Amole/ml/h, P=0.023; CRP: 4.10 vs. 1.55 mg/l, P=0.002;
WBC: 7.8 vs. 6.0103 counts/Al, P <0.001). Median CRP and
SAA levels were also higher in patients with Type 2 diabetes
mellitus (n =12) than those without the disease (n =81) (CRP:
6.90 vs. 1.85 mg/l, P=0.001; SAA: 4.8 vs. 2.5 mg/l,
P=0.014). Furthermore, patients with a history of hypertension
(n=42) had higher PLTP activity (15.36 Amol/ml/h) than did
those without (n =51) (14.55 Amol/ml/h) (P=0.041).
Since atherosclerosis involves inflammatory processes, we
also investigated whether the extent of the disease at random-
Table 3
Interrelationship among inflammatory markers and PLTP
CRP SAA Fibrinogen IL-6 WBC
rs P rs P rs P rs P rs P
SAA (n =93) 0.661 <0.001
Fibrinogen (n =89) 0.572 <0.001 0.349 <0.001
IL-6 (n =88–92) 0.321 0.002 0.283 0.006 0.130 0.229
WBC (n =89–93) 0.264 0.010 0.143 0.172 0.308 0.003 0.051 0.628
PLTP (n =89–93) 0.332 0.001 0.239 0.021 0.042 0.698 0.125 0.235 0.133 0.203
rs=Spearman rank correlation coefficient. P0.01 are in bold type.
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matory risk factors. Cumulative number of cigarettes smoked
over the years and a history of hypertension were correlated
positively with mean proximal % stenosis (rs=0.339, P=0.001)
and (rs=0.283, P=0.008), respectively. The median angio-
graphic score of patients who smoked more cigarettes (i.e.,
above the median) (35.59% stenosis) or with a history of
hypertension (38.08% stenosis) was significantly higher
(P <0.01) than those who smoked fewer cigarettes (below the
median) (31.11% stenosis) or without hypertension (31.39%
stenosis). None of the inflammatory markers or lipid parameters
measured at randomization in this 93-patient subgroup was
significantly associated with the patient’s angiographic score.
3.4. Factors contributing to variability in plasma PLTP activity
Multiple linear regression analysis was used to determine the
relevance of the variables that correlated with PLTP at P <0.05
in multivariate analyses in predicting plasma PLTP activity.
Both forward and backward stepwise models were carried out.
When cumulative cigarette smoking (pack-years) along with the
metabolic and lipid variables in Table 5 except Lp(A-I) were
included in the model, log CRP and BMI were significantly
associated with plasma PLTP activity with an R2 of 0.159 (Table
6, model 1). In the 56 patients with Lp(A-I) data, inclusion of
this variable in the analysis showed that Lp(A1), diastolic blood
pressure, glucose, and cumulative cigarette smoking (pack-
years) contributed significantly towards the variability of
plasma PLTP activity with an R2 of 0.506 (Table 6, model 2).Table 4
Cardiovascular disease risk factors showing significant correlation with PLTP, CRP
PLTP CRP SA
rs P rs P rs
BMI 0.292 0.004 0.293 0.004 0.3
Insulin 0.311 0.003 0.206 0.049 0.0
Glucose 0.187 0.072 0.343 <0.001 0.3
HOMA 0.327 0.001 0.295 0.004 0.2
Diastolic BP 0.317 0.004 0.184 0.100 0.3
HDL-TG 0.130 0.214 0.115 0.272 0.2
Apo A-I 0.243 0.019 0.085 0.418 0.2
Apo B 0.281 0.006 0.230 0.027 0.2
Apo E 0.264 0.011 0.332 0.001 0.3
LpA-I 0.472 <0.001 0.325 0.015 0.3
Numbers are from 92 or 93 subjects with the exception of those for blood pressure (n
are in bold type.4. Discussion
The pathogenesis of atherosclerosis involves inflammatory
processes. As such, CVD is a state of chronic inflammation.
CRP, SAA, fibrinogen, IL-6, and WBC are biological inflam-
matory markers that have been associated with the prevalence or
severity of CVD [13–15]. CRP, SAA, and fibrinogen are acute
phase reactants, and their plasma levels were significantly
correlated with one another in the 93 HATS patients included in
this study (Table 3). Interleukin-6, one of the regulators of
hepatic synthesis of CRP and SAA, was also associated
significantly with these two proteins. Of the five inflammatory
markers studied, plasma PLTP activity had the strongest positive
correlation with CRP, followed by SAA, the two well-studied
plasma surrogates of inflammatory activity. A significant
positive correlation between PLTP and CRP has been reported
in post surgery patients with bacterial infection or sepsis [10] and
in intensive care patients with a severe acute phase reaction [11].
In addition to an increase in PLTP levels in acute inflammation,
we now show that plasma PLTP activity increases with
increasing CRP level in CVD, a state of chronic inflammation.
A similar association also has been reported recently in subjects
with Type 2 diabetes mellitus [24]. It should be noted that our
study was limited to CVD subjects with low HDL. It is possible
that the various relationships observed between PLTP and
inflammatory markers or CVD risk factors may be different in
a CVD cohort with a broader range of HDL levels or in a
cohort without CVD. Although our observations were based on
a subset (93 of 160) of the whole baseline study, the, SAA, IL-6, or WBC
A IL-6 WBC
P rs P rs P
50 <0.001 0.126 0.230 0.161 0.122
97 0.318 0.000 0.997 0.112 0.287
93 <0.001 0.067 0.524 0.172 0.099
23 0.032 0.032 0.763 0.061 0.567
05 0.006 0.150 0.183 0.010 0.926
77 0.007 0.242 0.020 0.016 0.882
85 0.006 0.056 0.598 0.035 0.742
82 0.006 0.045 0.668 0.308 0.003
70 <0.001 0.338 0.001 0.043 0.683
76 0.004 0.373 0.005 0.135 0.321
=81) and Lp(A-I) (n =56). rs=Spearman rank correlation coefficient. P0.01
Table 5
Linear association between PLTP and CRP controlling for metabolic and
lipoprotein factors
Controlling factor PLTP vs. log CRP
Standardized coefficient P value
None 0.336 0.001
BMI 0.272 0.008
Insulin 0.299 0.004
Glucose 0.301 0.005
HOMA 0.302 0.004
Diastolic BP 0.296 0.007
Apo B 0.298 0.004
Apo E 0.297 0.004
Lp(A-I) 0.237 0.061
Numbers are from 92 or 93 subjects except with blood pressure measurements
(n =81) and Lp(A-I) (n =56). P0.01 are in bold type.
Table 6
Factors contributing to variability in plasma PLTP activity in multiple linear
regression analyses
Variable Standardized
coefficient
P value
Model 1 (R2=0.159)
Log CRP 0.272 0.008
BMI 0.225 0.028
Model 2 (R2=0.506)
Lp(A-I) 0.405 <0.001
Diastolic blood pressure 0.367 0.001
Glucose 0.294 0.008
Cigarette smoking (pack-years) 0.227 0.038
Variables considered were cigarette smoking and the variables in Table 5 either
excluding Lp (A-I) (model 1) or including Lp(A-I) (model 2).
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istics reported for the entire HATS patient population [17].
Consistent with previous studies, PLTP activity, CRP, and
SAA levels were positively associated with BMI [13,24,25]
and apo E [10], and cigarette smoking increased fibrinogen
level [26], WBC counts [26,27] and PLTP activity [28]. PLTP,
CRP and SAA were also positively associated with HOMA,
glucose and/or insulin, biochemical indicators of glucose
metabolism. These findings are consistent with the observation
of Riemens et al. [29,30], who found an inverse relationship
between PLTP activity and insulin sensitivity in non-diabetic
and diabetic subjects. It is interesting to note that, in addition to
their correlations with markers of abnormalities in glucose
metabolism, both PLTP and SAA were correlated with BMI,
diastolic blood pressure, and apo B, all of which are increased
in metabolic syndrome [31,32]. Thus, this study, together with
our previous work [33], confirms that PLTP activity is
associated with several features of the metabolic syndrome
[25]. Multiple regression analysis also showed that much of the
variability in plasma PLTP activity in this study was explained
by Lp(A-I), CRP, BMI, diastolic blood pressure, glucose, and
cumulative cigarette smoking (Table 6).
Apo E is often associated with increased presence of
atherogenic triglyceride-rich and remnant lipoproteins. Here,
we find that it is significantly and positively associated with
CRP, SAA, and IL-6. Little has been reported regarding the
relationship between apo E level and inflammatory markers. The
positive association between apo E and CRP is consistent with a
recent study showing that in patients with chronic renal failure,
significant reduction of apo E by atorvastatin was also associated
with reduction in CRP [34]. Contrary to our observation, Bach-
Ngohou found a strong inverse relation between CRP and apo E
in the plasma of obese healthy women [35]. The reason for this
discrepancy is not clear. It may be related to differences in the
study population and the nature of apo E-containing lipoproteins
in the plasma. In the healthy obese women with normal HDL
cholesterol level, greater than 70% of apo E was in non-apo B-
containing lipoproteins, and the negative association between
apo E and CRP was confined to this fraction of apo E [35]. Since
our patients had low HDL cholesterol, it is likely that relatively
more apo E in our patients were apo B-associated.We did not observe any significant association between
HDL cholesterol and the inflammatory factors. However, we
find that PLTP, SAA, and IL-6 were all positively and
significantly associated with plasma LpA-I level, but not with
Lp(A-I, A-II) which was the major population of HDL particles
in this study population [18]. The reason for the selective
association is not clear. It may reflect a compensatory response
of the more cardio-protective Lp(A-I) particles during inflam-
mation to remove mediators or oxidative products of inflam-
mation [36]. The positive association between Lp(A-I) and
some of the inflammatory markers is somewhat unexpected as
HDL is an inverse risk factor of CVD. Particles of multiple
sizes exist in Lp(A-I). It should be noted that the Lp(A-I) of the
subjects in this study contained predominantly small particles
with a electrophoretic mobility [18], a pro-atherogenic size
profile. Large Lp(A-I) particles may not exhibit the same
relationship with the inflammatory markers as the small Lp(A-
I) particles. Although CRP is usually not associated with HDL
[37], interestingly Lp(A-I) was the one controlling factor that
had the most effect on its association with PLTP (Table 5).
Also, when both Lp(A-I) and CRP were included in multiple
regression analysis, only Lp(A-I) was significantly associated
with plasma PLTP activity.
We found a significant positive correlation of apo B with
plasma PLTP activity in our predominantly male CVD patients.
In our earlier studies we reported that apo B is positively
correlated with PLTP activity in premenopausal women [38]
and in non-diabetic women but not in non-diabetic men [33].
Colhoun et al. [39] reported that apo B was positively
correlated with PLTP activity in male and female type 1
diabetics but not in non-diabetics. The lack of correlation of
apo B with PLTP activity in some groups may be related to
both the specific spread of PLTP activity and apo B levels in
these groups and the influence of the confounding variables,
such as hepatic lipase [38]. Interestingly, we also found that
apo B was positively correlated with SAA and white blood
cells levels. Since both the elevation of apo B and chronic
inflammation are common in CVD, this finding is not
unexpected, as it is likely that the chronic inflammatory state
influences apo B levels.
The physiological significance of a positive PLTP response
to inflammation is unclear. It has been suggested that an
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may enable more transfer of phospholipid to cells to maintain
membrane integrity under condition of inflammatory stress
[10,11]. We have shown that PLTP can bind ABCA1 and
promote cell cholesterol efflux [6,9]. Along with its ability to
generate preh HDL [7], the preferred acceptor of cell
cholesterol, an increase in PLTP activity during inflammation
may also enhance cholesterol efflux from macrophages.
Consistent with this, increased presence of PLTP has been
found in arterial smooth muscle cells and macrophages in
atherosclerotic lesion compared to non-atherosclerotic coro-
nary artery, and is increased with cholesterol-loading of
macrophages [16]. Since PLTP also binds lipopolysaccharide
[5], its increase during inflammation could promote the transfer
of mediators of infection and inflammation.
It is still unclear whether PLTP promotes or inhibits
atherogenesis. The anti-atherogenic potential of PLTP resides
in its ability to facilitate cholesterol efflux from cholesterol-
loaded cells [6,9,16]. Mechanisms by which PLTP might
promote atherosclerosis include its putative effect on apo B
secretion [40,41], reducing the availability of vitamin E to
atherogenic lipoproteins [42,43], and by mediating retention of
HDL on vascular extracellular matrix [16]. PLTP has been
shown in vitro to increase HDL binding to biglycan [16], a
proteoglycan that accumulates in human atherosclerotic plaques.
It is intriguing that both PLTP and SAA, molecules that have
been implicated in plaque lipoprotein retention [16,44], are
associated primarily with Lp(A-I) particles. The implications of
these associations in atherogenesis require further exploration.
In summary, this study shows for the first time that plasma
PLTP activity is associated positively with CRP in CVD, a
state of chronic inflammation. Our findings, however, do not
demonstrate whether PLTP promotes or inhibits atherogenesis.
Reports showing elevated PLTP activity associated with type 1
[45] and type 2 diabetes [46], obesity [47,48], as well as with
coronary disease patients [49] have given support to the idea
that PLTP is pro-atherogenic. Further studies are warranted to
explore the physiological role of PLTP in inflammation and in
atherogenesis.Acknowledgements
This study was supported by grants from the National
Institutes of Health HL30086, HL49546, DK35816 (Clinical
Nutrition Research Unit), and DK17074 (Diabetes Endocri-
nology Research Center), and by a grant from Merck and Co
Inc. and Upsher-Smith Laboratories.References
[1] J.J. Albers, A.-Y. Tu, G. Wolfbauer, M.C., S.M. Marcovina, Molecular
biology of phospholipid transfer proteins, Curr. Opin. Lipidol. 7 (1996)
88–93.
[2] A.R. Tall, S. Krumholz, T. Olivecrona, R.J. Deckelbaum, Plasma
phospholipid transfer protein enhances transfer and exchange of phos-
pholipids between very low-density lipoproteins and high-density lipo-
proteins during lipolysis, J. Lipid Res. 26 (1985) 842–851.[3] H.I. Nishida, T. Nishida, Phospholipid transfer protein mediates transfer of
not only phosphotidylcholine but also cholesterol from phosphotidylcho-
line-cholesterol vesicles to high density lipoproteins, J. Biol. Chem. 272
(1997) 6959–6964.
[4] C. Desrumaux, V. Deckert, A. Athias, D. Masson, G. Lizard, V. Palleau, P.
Gambert, L. Lagrost, Plasma phospholipid transfer protein prevents
vascular endothelium dysfunction by delivering alpha-tocopherol to
endothelial cells, FASEB J. 13 (1999) 883–892.
[5] E. Hailman, J.J. Albers, G. Wolfbauer, A.-Y. Tu, S.D. Wright, Neutral-
ization and transfer of lipopolysaccharide by phospholipid transfer
protein, J. Biol. Chem. 271 (1996) 12172–12178.
[6] J.F. Oram, G. Wolfbauer, A.M. Vaughan, C. Tang, J.J. Albers,
Phospholipid transfer protein interacts with and stabilizes ATP-binding
cassette transporter A1 and enhances cholesterol efflux from cells, J. Biol.
Chem. 278 (2003) 52379–52385.
[7] J. Huuskonen, V.M. Olkkonen, M. Jauhiainen, C. Ehnholm, The impact of
phospholipid transfer protein (PLTP) on HDL metabolism, Atherosclero-
sis 155 (2001) 269–281.
[8] A. Van Tol, M. Jauhiainen, R. De Crom, C. Ehnholm, Role of
phospholipid transfer protein in high-density lipoprotein metabolism:
insights from studies in transgenic mice, Int. J. Tissue React. XXII (2000)
79–84.
[9] G. Wolfbauer, J.J. Albers, J.F. Oram, Phospholipid transfer protein
enhances removal of cellular cholesterol and phospholipids by high-
density lipoprotein apolipoproteins, Biochim. Biophys. Acta 1439 (1999)
65–76.
[10] S. Barlage, D. Frohlich, A. Bottcher, M. Jauhiainen, H.P. Muller, F.
Noetzel, G. Rothe, C. Schutt, R.P. Linke, K.J. Lackner, C. Ehnholm, G.
Schmitz, ApoE-containing high density lipoproteins and phospholipid
transfer protein activity increase in patients with a systemic inflammatory
response, J. Lipid Res. 42 (2001) 281–290.
[11] P.J. Pussinen, J. Metso, E. Malle, S. Barlage, T. Palosuo, W. Sattler, G.
Schmitz, M. Jauhiainen, The role of plasma phospholipid transfer protein
(PLTP) in HDL remodeling in acute-phase patients, Biochim. Biophys.
Acta 1533 (2001) 153–163.
[12] R. Ross, Atherosclerosis: an inflammatory disease, N. Engl. J. Med. 340
(1999) 115–126.
[13] J.R. Delanghe, M.R. Langlois, D. De Bacquer, R. Make, P. Capel, L. Van
Renterghem, G.D. Backer, Discriminative value of serum amyloid A and
other acute-phase proteins for coronary heart disease, Atherosclerosis 160
(2002) 471–476.
[14] G.J. Blake, P.M. Ridker, Novel clinical markers of vascular wall
inflammation, Circ. Res. 89 (2001) 763–771.
[15] L. Lind, Circulating markers of inflammation and atherosclerosis,
Atherosclerosis 169 (2003) 203–214.
[16] K.D. O’Brien, S. Vuletic, T.O. McDonald, G. Wolfbauer, K. Lewis, A-Y.
Tu, S. Marcovina, T.N. Wight, A. Chait, J.J. Albers, Cell-associated and
extracellular phospholipid transfer protein in human coronary atheroscle-
rosis, Circulation 108 (2003) 270–274.
[17] B.G. Brown, X.Q. Zhao, A. Chait, L.D. Fisher, M.C. Cheung, J.S. Morse,
A.A. Dowdy, E.K. Marino, E.L. Bolson, P. Alaupovic, J. Frohlich, J.J.
Albers, Simvastatin and niacin, antioxidant vitamins, or the combination
for the prevention of coronary disease, N. Engl. J. Med. 345 (2001)
1583–1592.
[18] M.C. Cheung, X.-Q. Zhao, A. Chait, J.J. Albers, B.G. Brown, Antioxidant
supplements block the response of HDL to simvastatin-niacin therapy in
patients with coronary artery disease and low HDL, Arterioscler. Thromb.
Vasc. Biol. 21 (2001) 1320–1326.
[19] M.C. Cheung, G. Wolfbauer, J.J. Albers, Plasma phospholipid mass
transfer rate: relationship to plasma phospholipid and cholesteryl ester
transfer activities and lipid parameters, Biochim. Biophys. Acta 1303
(1996) 103–110.
[20] M.C. Cheung, J.J. Albers, Characterization of lipoprotein particles
isolated by immunoaffinity chromatography: particles containing A-I
and A-II and particles containing A-I but no A-II, J. Biol. Chem. 258
(1984) 12201–12209.
[21] D.R. Matthews, J.P. Hosker, A.S. Rudenski, B.A. Naylor, D.F. Treacher,
R.C. Turner, Homeostasis model assessment: insulin resistance and beta-
M.C. Cheung et al. / Biochimica et Biophysica Acta 1762 (2006) 131–137 137cell function from fasting plasma glucose and insulin concentrations in
man, Diabetologia 28 (1985) 412–419.
[22] M.C. Cheung, G. Wolfbauer, B.G. Brown, J.J. Albers, Relationship
between plasma phospholipid transfer protein activity and HDL sub-
classes among patients with low HDL and cardiovascular disease,
Atherosclerosis 142 (1999) 201–205.
[23] M.C. Cheung, G. Wolfbauer, H. Kennedy, B.G. Brown, J.J. Albers,
Plasma phospholipid transfer protein activity in patients with low HDL
and cardiovascular disease treated with simvastatin and niacin, Biochim.
Biophys. Acta 1537 (2001) 117–124.
[24] K.C.B. Tan, S.W.M. Shiu, Y. Wong, S. Tam, Plasma phospholipid transfer
protein activity and subclinical inflammation in type2 diabetes mellitus,
Atherosclerosis 178 (2005) 365–370.
[25] S. Kaser, A. Sandhofer, B. Foger, C.F. Ebenbichler, B. Igelseder, L.
Malaimare, B. Paulweber, J.R. Patsch, Influence of obesity and insulin
sensitivity on phospholipid transfer protein activity, Diabetologia 44
(2001) 1111–1117.
[26] L.A. Bazzano, P. Muntner, S. Vupputuri, P.K. Whelton, Relationship
between cigarette smoking and novel risk factors for cardiovascular
disease in the United States, Ann. Intern. Med. 138 (2003) 891–897.
[27] M.R. Smith, A.L. Kinmonth, R.N. Luben, S. Bingham, N.E. Day, N.J.
Wareham, A. Welch, K.-T. Khaw, Smoking status and differential white
cell count in men and women in the EPIC-Norfolk population,
Atherosclerosis 169 (2003) 331–337.
[28] R.P.F. Dullaart, K. Hoogenberg, B.D. Dikkeschei, A. van Tol, Higher
plasma lipid transfer protein activity and unfavorable lipoprotein changes
in cigarette-smoking men, Arterioscler. Thromb. 14 (1994) 1581–1585.
[29] S.C. Riemens, A. van Tol, W.J. Sluiter, R.P. Dullaart, Plasma phospholipid
transfer protein activity is related to insulin resistance: impaired acute
lowering by insulin in obese Type II diabetic patients, Diabetologia 41
(1998) 929–934.
[30] S.C. Riemens, A. van Tol, B.K. Stulp, R.P. Dullaart, Influence of insulin
sensitivity and the TaqIB cholesteryl ester transfer protein gene polymor-
phism on plasma lecithin:cholesterol acyltransferase and lipid transfer
protein activities and their response to hyperinsulinemia in non-diabetic
men, J. Lipid Res. 40 (1999) 1467–1474.
[31] K.D. O’Brien, B.J. Brehm, R.J. Seeley, J. Bean, M.H. Wener, S. Daniels,
D.A. D’Alessio, Diet-induced weight loss is associated with decreases in
plasma serum amyloid A and C-reactive protein independent of dietary
macronutrient composition in obese subjects, J. Clin. Endocrinol. Metab.
90 (2005) 2244–2249.
[32] R.H. Knopp, B. Retzlaff, B. Fish, C. Walden, S. Wallick, M. Anderson, K.
Aikawa, S.E. Kahn, Effects of insulin resistance and obesity on
lipoproteins and sensitivity to egg feeding, Arterioscler. Thromb. Vasc.
Biol. 23 (2003) 1437–1443.
[33] M.C. Cheung, R.H. Knopp, B. Retzlaff, H. Kennedy, G. Wolfbauer, J.J.
Albers, Association of plasma phospholipid transfer protein activity with
IDL and buoyant LDL: impact of gender and adiposity, Biochim. Biophys.
Acta 1587 (2002) 53–59.
[34] A. Ikejiri, T. Hirano, S. Murayama, G. Yoshino, A. Guchiken, T. Hyodo,
T. Taira, M. Adachi, Effects of atorvastatin on triglyceride-rich lipopro-
teins, low-density lipoprotein subclass, and C-reactive protein in hemo-
dialysis patients, Metabolism 53 (2004) 1113–1117.
[35] K. Bach-Ngohou, K.H. Nazih, F. Nazih-Sanderson, Y. Zair, D. Le Carrer,
M. Krempf, J.M. Bard, Negative and independent influence of apolipo-
protein E on C-reactive protein (CRP) concentration in obese adults.
Potential anti-inflammatory role of apoE in vivo, Intl. J. Obes. 25 (2001)
1752–1758.[36] J.R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, A. von
Eckardstein, HDL and arteriosclerosis: beyond reverse cholesterol
transport, Atherosclerosis 161 (2002) 1–16.
[37] F.C. De Beer, A.K. Soutar, M.L. Baltz, I.M. Trayner, A. Feinstein, M.B.
Pepys, Low density lipoprotein and very low density lipoprotein are
selectively bound by aggregated C-reactive protein, J. Exp. Med. 156
(1982) 230–242.
[38] S.J. Murdoch, M.C. Carr, J.E. Hokanson, J.D. Brunzell, J.J. Albers,
PLTP activity in premenopausal women. Relationship with lipoprotein
lipase, HDL, LDL, body fat, and insulin resistance, J. Lipid Res. 41
(2000) 237–244.
[39] H.M. Colhoun, M.R. Taskinen, J.D. Otvos, P. Van Den Berg, J. O’Connor,
A. van Tol, Relationship of phospholipid transfer protein activity to HDL
and apolipoprotein B-containing lipoproteins in subjects with and without
type 1 diabetes, Diabetes 51 (2002) 3300–3305.
[40] J. Lie, R. de Crom, T. van Gent, R. van Haperen, L. Scheek, I. Lankhuizen,
A. van Tol, Elevation of plasma phospholipid transfer protein in transgenic
mice increases very low density lipoprotein secretion, J. Lipid Res. 43
(2002) 1875–1880.
[41] X.C. Jiang, S. Qin, C. Qiao, K. Kawano, M. Lin, A. Skold, X. Xiao,
A.R. Tall, Apolipoprotein B secretion and atherosclerosis are decreased
in mice with phospholipid-transfer protein deficiency, Nat. Med. 7 (2001)
847–852.
[42] X.C. Jiang, A.R. Tall, S. Qin, M. Lin, M. Schneider, F. Lalanne, V.
Deckert, C. Desrumaux, A. Athias, J.L. Witztum, L. Lagrost, Phospho-
lipid transfer protein deficiency protects circulating lipoproteins from
oxidation due to the enhanced accumulation of vitamin E, J. Biol. Chem.
277 (2002) 31850–31856.
[43] M. Schneider, B. Verges, A. Klein, E.R. Miller, V. Deckert, C. Desrumaux,
D. Masson, P. Gambert, J.M. Brun, J. Fruchart-Najib, D. Blache, J.L.
Witztum, L. Lagrost, Alterations in plasma vitamin E distribution in type 2
diabetic patients with elevated plasma phospholipid transfer protein
activity, Diabetes 53 (2004) 2633–2639.
[44] K.D. O’Brien, T.O. McDonald, V. Kunjathoor, E.A. Knopp, K. Lewis, R.
Lopez, A. Chait, T.N. Wight, F.C. deBeer, R.C. LeBoeuf, Serum amyloid
A and lipoprotein retention in murine models of atherosclerosis,
Arterioscler. Thromb. Vasc. Biol. 25 (2005) 785–790.
[45] H.M. Colhoun, L.M. Scheek, M.B. Rubens, T. Van Gent, S.R.
Underwood, J.H. Fuller, A. Van Tol, Lipid transfer protein activities in
type 1 diabetic patients without renal failure and nondiabetic control
subjects and their association with coronary artery calcification, Diabetes
50 (2001) 652–659.
[46] S. Riemens, A. van Tol, W. Sluiter, R. Dullaart, Elevated plasma
cholesteryl ester transfer in NIDDM: relationships with apolipoprotein
B-containing lipoproteins and phospholipid transfer protein, Atheroscle-
rosis 140 (1998) 71–79.
[47] S. Kaser, A. Sandhofer, B. Foger, C.F. Ebenbichler, B. Igelseder, L.
Malaimare, B. Paulweber, J.R. Patsch, Influence of obesity and insulin
sensitivity on phospholipid transfer protein activity, Diabetologia 44
(2001) 1111–1117.
[48] R.P. Dullaart, W.J. Sluiter, L.D. Dikkeschei, K. Hoogenberg, A. Van Tol,
Effect of adiposity on plasma lipid transfer protein activities: a possible
link between insulin resistance and high density lipoprotein metabolism,
Eur. J. Clin. Invest. 24 (1994) 188–194.
[49] A. Schlitt, C. Bickel, P. Thumma, S. Blankenberg, H.J. Rupprecht, J.
Meyer, X.C. Jiang, High plasma phospholipid transfer protein levels as a
risk factor for coronary artery disease, Arterioscler. Thromb. Vasc. Biol.
23 (2003) 1857–1862.
